No abstract available
Keywords:
Immune-related adverse events; Immunotherapy; NSCLC; PD-1 inhibitors; Severe hepatitis.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Drug-Related Side Effects and Adverse Reactions / drug therapy*
-
Drug-Related Side Effects and Adverse Reactions / etiology
-
Drug-Related Side Effects and Adverse Reactions / pathology
-
Hepatitis / drug therapy*
-
Hepatitis / etiology
-
Hepatitis / pathology
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / immunology
-
Lung Neoplasms / pathology
-
Male
-
Retreatment / methods*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
pembrolizumab